Aktienanalyse zu ENDRA Life Sciences Inc (NDRA)NDRAENDRA Life Sciences Inc

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

NDRA appears to be a good buy right now due to its recent price momentum and improving financial indicators. The stock has shown a 5-day change of +11.47% and a year-to-date change of +16.67%, indicating positive short-term performance. Additionally, the recent RSI of 57.39 suggests that the stock is not overbought, leaving room for further gains. However, investors should be cautious of the significant net losses reported, with a net income of -3,169,209 USD in Q4 2025, which poses a risk to the company's financial stability.